Monday, 20 Nov 2017

You are here

Obesity Associated with Late-Onset Psoriatic Arthritis

A recent study reports that obesity is linked to late-onset psoriasis and psoriatic arthritis (PsA).  By contrast being of normal weight may be associated with an earlier onset of the disease adn HLA-B27.

Patients with early PsA were compared to those without arthritis (PsC), with regard to their body mass index (BMI) and HLA risk alleles for psoriatic disease (HLA-B*27, B*3901, B*3801, B*0801, B*4402, B*4403, and C*0602). A case-controlled designed was utilized to detect associations. 

Obesity was more common among the 314 patients with early PsA compared to 498 PsC patients (OR 1.77; p = 0.002).

Higher BMI was significantly associated with older age at onset for both PsA and psoriasis (p =  0.009).

HLA-B*27 was higher in patients with normal weight compared with those with higher BMI (p = 0.002).

Body weight significantly influences the onset and expression of psoriatic disease.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

MTX Doubles Hepatotoxicity Risk in Psoriasis Patients

A study from the University of Pennsylvania Perelman School of Medicine was published in the Journal of Investigative Dermatology showing that the risk of incident liver disease doubled when patients with psoriasis (PsO) or psoriatic arthritis (PsA) take methotrexate (MTX), but not when MTX is used in rheumatoid arthritis. (Citation source https://buff.ly/2i9qizC)

Several Agents Score on Radiographic Progression in Psoriatic Arthritis

Reduction on radiographic progression has now become the standard of care in the therapies used to treat psoriatic arthritis and, during the 2017 ACR Meeting, several agents reported the results of their studies with radiographic endpoints.

IL-17 Inhibition with Secukinumab in PsA: X-Ray Outcomes

With the emergence of new MOAs for the treatment of psoriatic arthritis in recent years, the most burning question remained if newer agents would perform as well in terms of radiographic progression as they did in clinical domains.

Novartis Features Secukinumab Data at ACR 17

Novartis has announce it will present its long-term 4-year data in ankylosing spondylitis (AS) and 24-weeks data in psoriatic arthritis (PsA) to be presented at the 2017 ACR/ARHP Annual Meeting

Structural disease progression is a major concern for AS and PsA patients as it may prompt mobility loss - new data to provide further evidence on the efficacy of Cosentyx to reduce structural disease progression.

FDA Approves Simponi Aria for Psoriatic Arthritis and Ankylosing Spondylitis

Janssen Biotech, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) the treatment of adults with active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS).